Komplet remission af metastatisk duodenal cancer efter behandling med BRAF-hæmmer

Helene Benedikte Hansen; Julia Almer Bromann; Dan Høgdall; Jakob Hagen Vasehus Schou; Rikke Eefsen

doi:10.61409/V08250650

Komplet remission af metastatisk duodenal cancer efter behandling med BRAF-hæmmer

Helene Benedikte Hansen^*, Julia Almer Bromann, Dan Høgdall, Jakob Hagen Vasehus Schou, Rikke Eefsen

^*Corresponding author af dette arbejde

Afdeling for Kræftbehandling HGH

Abstract

Encorafenib, cetuximab, and binimetinib are targeted therapies developed for metastatic colorectal cancer with a BRAF V600E mutation. This case report describes a patient with metastatic duodenal cancer with a BRAF V600E mutation who achieved durable complete remission following this treatment. The case highlights the potential use of BRAF V600E targeted therapy in BRAF V600E-mutated duodenal cancer and the importance of molecular profiling in rare cancers. Further research is needed on the effect and safety of targeted therapy for small bowel adenocarcinoma.

Bidragets oversatte titel	Remission of metastatic duodenal cancer after treatment with BRAF inhibitor
Originalsprog	Dansk
Artikelnummer	V08250650
Tidsskrift	Ugeskrift for Laeger
Vol/bind	188
Udgave nummer	5
ISSN	0041-5782
DOI	https://doi.org/10.61409/V08250650
Status	Udgivet - 26 jan. 2026

Emneord

Humans
Proto-Oncogene Proteins B-raf/antagonists & inhibitors
Duodenal Neoplasms/drug therapy
Adenocarcinoma/drug therapy
Sulfonamides/therapeutic use
Antineoplastic Agents/therapeutic use
Male
Mutation
Remission Induction
Carbamates/therapeutic use
Middle Aged
Female

Adgang til dokumentet

10.61409/V08250650Licens: CC BY-NC-ND

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{425022224b00492d870fdfbdf3e99a55,

title = "Komplet remission af metastatisk duodenal cancer efter behandling med BRAF-h{\ae}mmer",

abstract = "Encorafenib, cetuximab, and binimetinib are targeted therapies developed for metastatic colorectal cancer with a BRAF V600E mutation. This case report describes a patient with metastatic duodenal cancer with a BRAF V600E mutation who achieved durable complete remission following this treatment. The case highlights the potential use of BRAF V600E targeted therapy in BRAF V600E-mutated duodenal cancer and the importance of molecular profiling in rare cancers. Further research is needed on the effect and safety of targeted therapy for small bowel adenocarcinoma.",

keywords = "Humans, Proto-Oncogene Proteins B-raf/antagonists \& inhibitors, Duodenal Neoplasms/drug therapy, Adenocarcinoma/drug therapy, Sulfonamides/therapeutic use, Antineoplastic Agents/therapeutic use, Male, Mutation, Remission Induction, Carbamates/therapeutic use, Middle Aged, Female",

author = "Hansen, \{Helene Benedikte\} and Bromann, \{Julia Almer\} and Dan H{\o}gdall and Schou, \{Jakob Hagen Vasehus\} and Rikke Eefsen",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2026",

month = jan,

day = "26",

doi = "10.61409/V08250650",

language = "Dansk",

volume = "188",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "5",

}

TY - JOUR

T1 - Komplet remission af metastatisk duodenal cancer efter behandling med BRAF-hæmmer

AU - Hansen, Helene Benedikte

AU - Bromann, Julia Almer

AU - Høgdall, Dan

AU - Schou, Jakob Hagen Vasehus

AU - Eefsen, Rikke

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2026/1/26

Y1 - 2026/1/26

N2 - Encorafenib, cetuximab, and binimetinib are targeted therapies developed for metastatic colorectal cancer with a BRAF V600E mutation. This case report describes a patient with metastatic duodenal cancer with a BRAF V600E mutation who achieved durable complete remission following this treatment. The case highlights the potential use of BRAF V600E targeted therapy in BRAF V600E-mutated duodenal cancer and the importance of molecular profiling in rare cancers. Further research is needed on the effect and safety of targeted therapy for small bowel adenocarcinoma.

AB - Encorafenib, cetuximab, and binimetinib are targeted therapies developed for metastatic colorectal cancer with a BRAF V600E mutation. This case report describes a patient with metastatic duodenal cancer with a BRAF V600E mutation who achieved durable complete remission following this treatment. The case highlights the potential use of BRAF V600E targeted therapy in BRAF V600E-mutated duodenal cancer and the importance of molecular profiling in rare cancers. Further research is needed on the effect and safety of targeted therapy for small bowel adenocarcinoma.

KW - Humans

KW - Proto-Oncogene Proteins B-raf/antagonists & inhibitors

KW - Duodenal Neoplasms/drug therapy

KW - Adenocarcinoma/drug therapy

KW - Sulfonamides/therapeutic use

KW - Antineoplastic Agents/therapeutic use

KW - Male

KW - Mutation

KW - Remission Induction

KW - Carbamates/therapeutic use

KW - Middle Aged

KW - Female

UR - https://www.scopus.com/pages/publications/105028999222

U2 - 10.61409/V08250650

DO - 10.61409/V08250650

M3 - Tidsskriftartikel

C2 - 41614250

SN - 0041-5782

VL - 188

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 5

M1 - V08250650

ER -

Komplet remission af metastatisk duodenal cancer efter behandling med BRAF-hæmmer

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater